Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street’s consensus price targets, and four of the five just beat their most recent EPS estimates. When a 64-year dividend raiser like Johnson & Johnson is raising 2026 EPS guidance to $11.45-$11.65 while still trading ... Dividend Aristocrats on Sale: 5 Decades-Long Raise...
Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street’s consensus price targets, and four of the five just beat their most recent EPS estimates. When a 64-year dividend raiser like Johnson & Johnson is raising 2026 EPS guidance to $11.45-$11.65 while still trading ... Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target
Sundry Photography Broadcom ( AVGO ) was upgraded by Erste Group on Friday after an earnings-related selloff on Thursday . Shares fell 2.2% in premarket trading. “The Group expects the very positive momentum to continue in the third quarter of the new financial year,” Erste Group analyst Hans Engel wrote in a note to clients. “Sales will amount to approximately USD 29.4 billion. This corresponds t...
Sundry Photography Broadcom ( AVGO ) was upgraded by Erste Group on Friday after an earnings-related selloff on Thursday . Shares fell 2.2% in premarket trading. “The Group expects the very positive momentum to continue in the third quarter of the new financial year,” Erste Group analyst Hans Engel wrote in a note to clients. “Sales will amount to approximately USD 29.4 billion. This corresponds to an increase of +89% Y/Y. Broadcom expects sales of AI semiconductors in particular to increase to USD 16 bn. The gross margin and the operating margin are expected to remain stable at a high level. The Group is growing much faster than its peers in the sector. The stock should benefit from the company's above-average prospects and therefore continue its upward trend.” Engel raised his rating on Broadcom to Buy from Hold. More on Broadcom Broadcom: The ASIC Boom Is Real, But So Is The Valuation Problem Broadcom Has Just Crashed - I'm Buying This Dip (Rating Upgrade) Broadcom Is Down 15%: Why I'm Selling Anyway (Rating Downgrade) Broadcom, Ciena lead tech stocks lower after lackluster guidance A look at Broadcom's chart after its post-earnings selloff
Sundry Photography Broadcom ( AVGO ) was upgraded by Erste Group on Friday after an earnings-related selloff on Thursday . Shares fell 2.2% in premarket trading. “The Group expects the very positive momentum to continue in the third quarter of the new financial year,” Erste Group analyst Hans Engel wrote in a note to clients. “Sales will amount to approximately USD 29.4 billion. This corresponds t...
Sundry Photography Broadcom ( AVGO ) was upgraded by Erste Group on Friday after an earnings-related selloff on Thursday . Shares fell 2.2% in premarket trading. “The Group expects the very positive momentum to continue in the third quarter of the new financial year,” Erste Group analyst Hans Engel wrote in a note to clients. “Sales will amount to approximately USD 29.4 billion. This corresponds to an increase of +89% Y/Y. Broadcom expects sales of AI semiconductors in particular to increase to USD 16 bn. The gross margin and the operating margin are expected to remain stable at a high level. The Group is growing much faster than its peers in the sector. The stock should benefit from the company's above-average prospects and therefore continue its upward trend.” Engel raised his rating on Broadcom to Buy from Hold. More on Broadcom Broadcom: The ASIC Boom Is Real, But So Is The Valuation Problem Broadcom Has Just Crashed - I'm Buying This Dip (Rating Upgrade) Broadcom Is Down 15%: Why I'm Selling Anyway (Rating Downgrade) Broadcom, Ciena lead tech stocks lower after lackluster guidance A look at Broadcom's chart after its post-earnings selloff
(RTTNews) - Uncertainty continue to linger over U.S.-Iran peace negotiations and the stakeholders are not hopeful of settling the Middle East conflict immediately.
(RTTNews) - Uncertainty continue to linger over U.S.-Iran peace negotiations and the stakeholders are not hopeful of settling the Middle East conflict immediately.
NoDerog/iStock Unreleased via Getty Images Brown-Forman Corporation ( BF.B ) reported the company’s fiscal Q4 results from the February-April quarter. As recent M&A talks with Pernod Ricard SA ( PDRDF ) ended , the focus is back on Brown-Forman’s own performance. The company reported impressive stabilization against a weak alcohol consumption trend, signaling the spirits producer’s strategy’s stre...
NoDerog/iStock Unreleased via Getty Images Brown-Forman Corporation ( BF.B ) reported the company’s fiscal Q4 results from the February-April quarter. As recent M&A talks with Pernod Ricard SA ( PDRDF ) ended , the focus is back on Brown-Forman’s own performance. The company reported impressive stabilization against a weak alcohol consumption trend, signaling the spirits producer’s strategy’s strength. Yet, the industry backdrop and increased input costs still weigh on Brown-Forman’s outlook; there isn’t reason for too much optimism yet. I upgraded my rating to Hold in my previous March article on the stock, titled “ Brown-Forman: There's Enough Reason To Turn Neutral ”. The stock has since returned 9%, slightly underperforming the S&P 500’s 15% gain. My Rating History on BF.B (Seeking Alpha) Brown-Forman’s Q4 Was Relatively Strong Brown-Forman showed stabilizing results in the Q4 report . Fourth quarter net sales grew by 2% organically to $912 million, fighting well against a sector-wide decline and the company’s own flat sales performance in the whole fiscal year. The topline result beat the analyst consensus estimate by $32 million; Wall Street assumed a slight sales decline. Excluding impairment charges and other one-off items, Brown-Forman’s organic adjusted operating income stayed flat year-on-year. While Brown-Forman’s gross margin and marketing expenses fluctuate, overall, the company’s cost savings have enabled stable profitability in a volatile operating environment. BF.B Q4'FY26 Investor Presentation I believe that despite not achieving earnings growth, Brown-Forman’s performance was quite good in the quarter when considering the sector environment – macroeconomic pressure and changing consumption preferences continue to weigh on alcohol sales in the U.S. and most other developed markets. Brown-Forman once again noted pressured consumer spending in the Q4 earnings call . The U.S. consumer sentiment has reached another new low. Diageo plc ( DEO ) and Perno...
Paul Bradbury/OJO Images via Getty Images Investment Overview The last time I covered MBX Biosciences ( MBX ) in a note for Seeking Alpha, it was December 2025 , so I feel an update is timely, especially given the company gave an "Obesity Day" presentation recently, and the stock is up ~15% on a one-month basis and >30% year-to-date. MBX completed its IPO in September 2024, raising ~$188m via the ...
Paul Bradbury/OJO Images via Getty Images Investment Overview The last time I covered MBX Biosciences ( MBX ) in a note for Seeking Alpha, it was December 2025 , so I feel an update is timely, especially given the company gave an "Obesity Day" presentation recently, and the stock is up ~15% on a one-month basis and >30% year-to-date. MBX completed its IPO in September 2024, raising ~$188m via the issuance of ~11.73m shares priced at $16 per share, and is "focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders." Canvuparatide The Lead Asset Has Important Upcoming Catalyst A company overview from the obesity day presentation is provided below: MBC company overview (presentation) As we can see, canvuparatide is the furthest advanced asset—a parathyroid hormone peptide prodrug (a compound with little pharmacological activity that metabolizes inside the body and converts into a pharmacologically active drug compound when triggered by a drug-metabolizing enzyme, or "DME"). There will be a presentation of Phase 2 study results and one-year follow-up data presented at the Endocrine Society’s ENDO 2026 annual meeting in Chicago on Saturday, June 13, MBX has promised , and a Phase 3 study is expected to initiate in Q3, which may imply management expects the Phase 2 data will be strong. HP affects ~120k people in the US and >250k in the US + Europe, MBX says, and there are no products on the market that address the underlying cause of the disease, which is parathyroid hormone ("PTH") deficiency. Yorvipath (palopegteriparatide), developed by Ascendis Pharma ( ASND ), is a once-daily PTH replacement therapy that is approved in the United States and European Union. The FDA approved the drug in August 2024, and it made sales of ~$230m in Q1 2026. Royalty Pharma ( RPRX ), which has purchased royalty rights to Yorvipath, speculates that the drug could earn ~$1.3bn in peak revenues. The advantage of canvupa...
While some residents are proud to host celebrations, others lament road closures and city’s transformation into a ‘theme park’ Concetta Chillemi was chatting to friends outside her shop next to Palermo’s gallery for modern art housed in a sublime baroque church in the city’s historic centre. A few metres away, an Italian TV crew had its camera trained on the tiny square in front of the church wher...
While some residents are proud to host celebrations, others lament road closures and city’s transformation into a ‘theme park’ Concetta Chillemi was chatting to friends outside her shop next to Palermo’s gallery for modern art housed in a sublime baroque church in the city’s historic centre. A few metres away, an Italian TV crew had its camera trained on the tiny square in front of the church where event staff in black T-shirts scurried around in the heat. They were preparing for the arrival of the British singer Dua Lipa and the actor Callum Turner, who over the next two days are celebrating their wedding in the Sicilian capital after exchanging vows in London last weekend. Continue reading...
G-III Apparel (GIII) delivered earnings and revenue surprises of +30.00% and +1.13%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
G-III Apparel (GIII) delivered earnings and revenue surprises of +30.00% and +1.13%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
ClearBridge Energy Midstream Opportunity ( EMO ) announced on Friday that the fund’s net assets were $1.12B, and its net asset value per share was $56.00 as of May 31, 2026,. The fund’s asset coverage ratio regarding senior indebtedness was 699%, and the fund's asset coverage ratio regarding total leverage was 520%. Source: press release More on ClearBridge Energy Midstream Opportunity Fund CEF In...
ClearBridge Energy Midstream Opportunity ( EMO ) announced on Friday that the fund’s net assets were $1.12B, and its net asset value per share was $56.00 as of May 31, 2026,. The fund’s asset coverage ratio regarding senior indebtedness was 699%, and the fund's asset coverage ratio regarding total leverage was 520%. Source: press release More on ClearBridge Energy Midstream Opportunity Fund CEF Insights: EMO - Opportunity In Structural Growth Of North American Energy EMO: Monthly Income From Midstream Companies With Some Tradeoffs ClearBridge Energy Midstream Opportunity Fund declares $0.36 dividend Dividend scorecard for ClearBridge Energy Midstream Opportunity Fund
Here are Friday's biggest calls on Wall Street: JPMorgan adds a positive catalyst watch on Qualcomm The firm said its sticking with its neutral rating but is bullish ahead of the company's investor day. " Qualcomm is set to host its highly anticipated Investor Day on June 24th, to discuss the next phase of the company's growth and diversification strategy amidst the rapid evolution of AI." Bank of...
Here are Friday's biggest calls on Wall Street: JPMorgan adds a positive catalyst watch on Qualcomm The firm said its sticking with its neutral rating but is bullish ahead of the company's investor day. " Qualcomm is set to host its highly anticipated Investor Day on June 24th, to discuss the next phase of the company's growth and diversification strategy amidst the rapid evolution of AI." Bank of America reiterates Nvidia as buy Bank of America said the stock is firing on all cylinders after a meeting with management. "Following 'GTC Taipei' CEO keynote on Monday we hosted NVDA CFO Colette Kress for a well-attended keynote on Thursday, and Sr. Director, IR Stewart Stecker for a bus tour investor meeting." UBS initiates Champion Homes and Cavco as buy UBS said the building companies are well positioned. "We initiate coverage on SKY & CVCO with Buy ratings, as we view both companies as potential beneficiaries of an affordability-challenged and underbuilt housing market that appears to be bottoming and poised to reaccelerate." Goldman Sachs initiates Concentra as buy Goldman said the occupation health company has "durable growth drivers." "We initiate coverage on shares of Concentra (CON ) with a Buy rating and a 12‑month price target of $30." BTIG downgrades Lululemon to hold from buy BTIG said it has "reduced visibility." "We downgrade LULU t o Neutral from Buy. While Q1 was largely in-line, the decel toward the end of the quarter suggests more work ahead, with Q2 sales set to decline for the first time post-COVID." Roth initiates Coya Therapeutics as buy Roth said it's bullish on the biotech company. "We initiate coverage of COYA with a Buy rating and 12-month PT of $12." Evercore ISI upgrades FormFactor to outperform from in line Evercore said it sees a compelling risk/reward for the semis testing company. "Upgrade to Outperform with $155 PT. based on 38x 2028 EPS of $5 discounted back to 2026. We think a higher multiple is justified given the AI tailwinds and exp...
Proponents say scheme could generate up to £2.7bn in five years by making travel around north of England easier A proposed travel card for northern England modelled on London’s Oyster system could save commuters up to £276 a year, data shows. Users would tap in and out across different transport networks and fares would be automatically capped at the cheapest available rate. Continue reading...
Proponents say scheme could generate up to £2.7bn in five years by making travel around north of England easier A proposed travel card for northern England modelled on London’s Oyster system could save commuters up to £276 a year, data shows. Users would tap in and out across different transport networks and fares would be automatically capped at the cheapest available rate. Continue reading...
Cem Karsan, founder of Kai Volatility Advisors and a recurring guest on Adam Taggart’s Thoughtful Money podcast, delivered a warning that cuts deeper than typical valuation concerns. The danger he sees is a slow erosion of purchasing power stretched across more than a decade, a regime most living investors have never personally invested through. The ... Cem Karsan Warns The S&P 500 Lost 40% in Rea...
Cem Karsan, founder of Kai Volatility Advisors and a recurring guest on Adam Taggart’s Thoughtful Money podcast, delivered a warning that cuts deeper than typical valuation concerns. The danger he sees is a slow erosion of purchasing power stretched across more than a decade, a regime most living investors have never personally invested through. The ... Cem Karsan Warns The S&P 500 Lost 40% in Real Terms Over 14 Years – And It Could Happen Again